I am a breastfeeding mother and i want to know if it is safe to use UNII-YOP6PX0BAO? Is UNII-YOP6PX0BAO safe for nursing mother and child? Does UNII-YOP6PX0BAO extracts into breast milk? Does UNII-YOP6PX0BAO has any long term or short term side effects on infants? Can UNII-YOP6PX0BAO influence milk supply or can UNII-YOP6PX0BAO decrease milk supply in lactating mothers?
- DrLact safety Score for UNII-YOP6PX0BAO is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of UNII-YOP6PX0BAO is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that UNII-YOP6PX0BAO does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of UNII-YOP6PX0BAO safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Antibacterial carbapenem beta-lactam with indications similar to imipenem.Intravenous administration every 8 hours. It is excreted in breast milk in a clinically insignificant amount (Sauberan 2012) and no problems have been observed in infants whose mothers took it (Festini 2004). Authorized pediatric use in infants and newborns. It is considered by experts to be compatible with breastfeeding (Rowe 2013). The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to altered intestinal flora (Benyamini 2005, Ito 1993, Kafetzis 1981).
Although no information is available on the use of UNII-YOP6PX0BAO during breastfeeding, milk levels appear to be low and beta-lactams are generally not expected to cause adverse effects in breastfed infants. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with beta-lactams, but these effects have not been adequately evaluated. Vaborbactam, which is available in the combination product Vabomere, has not been studied in nursing mothers, but the combination is expected to have similar concerns as with UNII-YOP6PX0BAO alone.
A mother received UNII-YOP6PX0BAO 1 gram IV every 8 hours for 7 days while exclusively breastfeeding her newborn. When questioned later, she stated that her infant had no oral thrush, watery diarrhea, or diaper dermatitis that required antifungal therapy during the month following her UNII-YOP6PX0BAO therapy.[1] An infant was breastfed (extent not stated) until the 4th month postpartum. At 2 months of age, his mother was given a 2-week course of tobramycin and UNII-YOP6PX0BAO (dosage not specified) for a cystic fibrosis exacerbation. The infant displayed no change in stool pattern during the maternal treatment and had normal renal function at 6 months of age.[2]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.